• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

BrainCool

0.72 SEK

+2.14 %

Less than 1K followers

BRAIN

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.14 %
-4.79 %
+32.41 %
+20.78 %
+27.68 %
-55.62 %
-66.53 %
-84.87 %
-59.53 %

BrainCool operates in the medical technology sector. The company develops products for medical cooling of the brain. The technology is developed as cooling pads that are applied to different parts of the patient's body, where the system controls body temperature. The products are used in the treatment of various serious conditions including stroke, cardiac arrest, as well as concussion and migraine. BrainCool was founded in 2010 and is headquartered in Lund.

Read more
Market cap
282.34M SEK
Turnover
567.06K SEK
Revenue
36.21M
EBIT %
-95.12 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/8
2026

Interim report Q2'26

11/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

Regulatory press release6/15/2026, 9:00 AM

BrainCool förstärker organisationen med två nyckelrekryteringar inom den kommersiella och kliniska verksamheten

BrainCool
Regulatory press release6/4/2026, 6:30 AM

BrainCool erhåller marknadsgodkännande i Taiwan

BrainCool
Regulatory press release5/20/2026, 1:05 PM

BrainCool AB (publ): kommuniké från årsstämman

BrainCool

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/12/2026, 8:15 AM

BrainCool lämnar fördjupad statusuppdatering om COTTIS 2-studien

BrainCool
Regulatory press release5/6/2026, 6:30 AM

BrainCool AB (publ) – Kvartalsrapport jan-mar 2026

BrainCool
Regulatory press release5/5/2026, 6:30 AM

BrainCool bjuder in till webcast om bolagets pågående kliniska studier PRINCESS 2 och COTTIS 2

BrainCool
Regulatory press release4/21/2026, 6:30 AM

Kallelse till årsstämma i BrainCool AB (publ)

BrainCool
Regulatory press release4/20/2026, 6:30 AM

BrainCool offentliggör årsredovisningen för verksamhetsåret 2025

BrainCool
Regulatory press release4/13/2026, 6:30 AM

BrainCool beslutar att låta Ekobrottsmyndigheten föra bolagets skadeståndsanspråk mot tidigare VD

BrainCool
Regulatory press release4/10/2026, 6:50 AM

BrainCool deltar vid Redeye Healthcare Day 2026

BrainCool
Regulatory press release3/25/2026, 5:56 PM

BrainCool informerar om pågående myndighetsärende

BrainCool
Regulatory press release3/16/2026, 7:00 AM

Positiva resultat från preklinisk studie vid Hiroshima University stöder behandling med RhinoChill® System för precisionskylning av hjärnan

BrainCool
Press release2/25/2026, 7:30 AM

Ny jämförande analys baserad på COTTIS 1-studien bekräftar förbättrad neurologisk återhämtning med RhinoChill® System vid akut stroke

BrainCool
Press release2/20/2026, 7:45 AM

Resultaten från pilotfasen i PRINCESS 2-studien av RhinoChill® System publicerade i den vetenskapliga tidskriften Critical Care

BrainCool
Regulatory press release2/20/2026, 7:00 AM

Valberedningen utsedd inför BrainCools årsstämma 2026

BrainCool
Regulatory press release2/18/2026, 7:30 AM

BrainCool AB (publ) – Bokslutskommuniké jan-dec 2025

BrainCool
Regulatory press release2/16/2026, 7:00 AM

BrainCool erhåller order på BrainCool™ System från bolagets globala distributör till ett värde uppgående till minst SEK 39 miljoner

BrainCool
Regulatory press release2/12/2026, 7:00 AM

BrainCool bjuder in till webcast med bolagets nya vd

BrainCool
Press release2/5/2026, 7:00 AM

BrainCool har erhållit ordrar på engångsprodukter till ett värde av SEK 9 miljoner

BrainCool
Press release1/23/2026, 7:00 AM

BrainCool inkluderar patient till COTTIS 2-studien av RhinoChill®

BrainCool